Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY ...

Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...

AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of ...

And Cerevel Therapeutics, which had positive early testing results for emraclidine, its drug that aims to treat schizophrenia ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...